Universitätsklinikum Ulm

Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment (2018) Bauer ECA, Schochter F, Widschwendter P, Degregorio A, Andergassen U, Friedl TWP, Fasching P, et al. Journal article Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients (2018) Nabieva N, Kellner S, Fehm T, Häberle L, De Waal J, Rezai M, Baier B, et al. Journal article Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer (2018) Banys-Paluchowski M, Fehm T, Janni W, Aktas B, Fasching P, Kasimir-Bauer S, Milde-Langosch K, et al. Journal article Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No. 015/082, November 2017) - Recommendations and Statements for Girls and Women (2018) Dittrich R, Kliesch S, Schuering A, Balcerek M, Baston-Buest DM, Beck R, Beckmann M, et al. Journal article Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study (2018) Nabieva N, Fehm T, Häberle L, De Waal J, Rezai M, Baier B, Baake G, et al. Journal article BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study (2018) Fasching P, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, et al. Journal article The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer (2018) Banys-Paluchowski M, Witzel I, Riethdorf S, Pantel K, Rack B, Janni W, Fasching P, et al. Journal article Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44) (2018) Untch M, Von Minckwitz G, Gerber B, Schem C, Rezai M, Fasching P, Tesch H, et al. Journal article Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial (2018) Hepp P, Fasching P, Beckmann M, Fehm T, Salmen J, Hagenbeck C, Jaeger B, et al. Journal article Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial (2018) Ignatiadis M, Litiere S, Rothe F, Riethdorf S, Proudhon C, Fehma T, Aalders K, et al. Journal article